N-acetylcysteine for Retinitis Pigmentosa
Trial Summary
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug N-acetylcysteine for retinitis pigmentosa?
Research shows that N-acetylcysteine (NAC) can improve vision and protect eye cells in people with retinitis pigmentosa by reducing oxidative stress (damage caused by harmful molecules). In a study, patients taking NAC had better visual function, and in animal models, NAC helped preserve eye cell structure and function over time.12345
Is N-acetylcysteine safe for humans?
How does the drug N-acetylcysteine differ from other treatments for retinitis pigmentosa?
N-acetylcysteine (NAC) is unique because it works by reducing oxidative stress, which helps protect and improve the function of cone cells in the eye, potentially slowing vision loss in retinitis pigmentosa. Unlike other treatments, NAC is taken orally as effervescent tablets, making it a convenient option for long-term use.12348
What is the purpose of this trial?
This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.
Research Team
Peter Campochiaro
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults over 18 with Retinitis Pigmentosa (RP), a condition leading to vision loss. Participants must consent to use their health information and understand the study's details. It excludes those with other eye diseases affecting central vision, active eye infections, or uncontrolled high blood pressure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive N-Acetylcysteine (NAC) at a dose of 1800 mg twice a day
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may continue receiving NAC to assess long-term safety and tolerability
Treatment Details
Interventions
- NAC effervescent tablets
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Zambon SpA
Industry Sponsor